TIL: Clinical Trials

11 trials of TIL, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 3 recruiting, 2 terminated, 1 active not recruiting. 11 Phase 1, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 111Completed 3, Recruiting 3, Terminated 2, Active not recruiting 1, Unknown 1, Withdrawn 1
Phase 24Recruiting 1, Terminated 1, Unknown 1, Withdrawn 1

Follow TIL: new trials by email Literature Review of TIL trials Research Report on TIL

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
E7 TCR-T cells, Aldesleukin - HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma
Phase 1 / Phase 2RecruitingChristian Hinrichs152025-08-112026-10-28
TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma
TILT-123, TIL, Cyclophosphamide - Metastatic Melanoma
Phase 1Active not recruitingTILT Biotherapeutics Ltd.92025-06-252026-03-05
Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
Tumor-infiltrating Lymphocytes (TIL), Nivolumab, Cyclophosphamide - Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Phase 1RecruitingH. Lee Moffitt Cancer Center and Research Institute202023-03-102026-09-16
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
KK-LC-1 TCR-T cells, Aldesleukin - Gastric Cancer, Breast Cancer
Phase 1RecruitingChristian Hinrichs302022-09-262026-10-28
OVSTAR TIL Trial (OVarian Cancer Co-STimulatory Antigen Receptor TIL Trial)
cyclophosphamide, fludarabine, IL-2 (Proleukin) - Ovarian Cancer Metastatic
Phase 1 / Phase 2WithdrawnImmetacyte Ltd2020-07-012020-12-16
Immunotherapy for the Treatment of Advanced Solid Tumor
TIL, Aldesleukin, Cyclophosphamide - Recurrence Tumor, Metastatic Cancer
Phase 1 / Phase 2UnknownTongji Hospital402020-04-282024-08-13
Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma
TIL, Interleukin-2, Fludarabine - Sarcoma
Phase 1CompletedH. Lee Moffitt Cancer Center and Research Institute92019-09-272026-02-20
Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors
TIL, Cyclophosphamide, Fludarabine - Solid Tumor, Adult
Phase 1TerminatedCentre Hospitalier Universitaire Vaudois62019-09-012021-03-18
TIL-ACT After NMA Chemo with IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL)
TIL, Cyclophosphamide, Fludarabine - Metastatic Melanoma
Phase 1CompletedCentre Hospitalier Universitaire Vaudois182018-02-212025-02-11
Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer
Tumor-infiltrating Lymphocytes (TIL), Nivolumab, Cyclophosphamide - Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer
Phase 1CompletedH. Lee Moffitt Cancer Center and Research Institute202017-10-112023-07-24
Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma
Cyclophosphamide, Fludarabine, Tumor Infiltrating Lymphocytes - Metastatic Melanoma, Skin Cancer
Phase 1 / Phase 2TerminatedNational Cancer Institute (NCI)32011-05-012015-01-27

Conditions studied

Melanoma (3)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Lung Neoplasms (2)  ·  Recurrence (2)  ·  Uterine Cervical Neoplasms (2)  ·  Adenocarcinoma (1)  ·  Anus Neoplasms (1)  ·  Breast Neoplasms (1)  ·  Carcinoma, Adenosquamous (1)  ·  Carcinoma, Squamous Cell (1)  ·  Neoplasm Metastasis (1)  ·  Oropharyngeal Neoplasms (1)  ·  Penile Neoplasms (1)  ·  Sarcoma (1)  ·  Skin Neoplasms (1)

Sponsors

H. Lee Moffitt Cancer Center and Research Institute (3)  ·  Centre Hospitalier Universitaire Vaudois (2)  ·  Christian Hinrichs (2)  ·  Immetacyte Ltd (1)  ·  National Cancer Institute (NCI) (1)  ·  TILT Biotherapeutics Ltd. (1)  ·  Tongji Hospital (1)

Countries

United States (6)  ·  Switzerland (2)  ·  China (1)  ·  Denmark (1)  ·  United Kingdom (1)

Top investigators

Christian S Hinrichs, MD (2)  ·  George Coukos, MD, PhD (2)  ·  Ben Creelan, M.D. (1)  ·  Ben Creelan, MD, MS (1)  ·  Fiona Thistlethwaite, PhD, MRCP (1)  ·  Hui Wang, MD (1)  ·  Inge Marie Svane (1)  ·  John Mullinax, MD (1)  ·  Steven A Rosenberg, M.D. (1)

Results publications

PMID 34385708, PMID 38490980

NIH funding

2019 (1), K08CA252642 (1)